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Background: Despite the marked efficacy of 1st generation DES in reducing the need for repeat lesion revascularization, the presence of durable 
polymers has raised concerns regarding their long-term safety. The Supralimus stent (SS) combines a stainless steel platform with bioabsorbable 
polymer loaded with sirolimus. We sought to determine the safety and clinical effectiveness of this novel DES in ACS pts.
Methods: The E-SERIES Registry is an open-labeled, multicenter, non-randomized study with non-selected pts treated with SS. In the present 
analysis we included all patients with ACS as initial presentation, primarily aiming to define the long-term (up to 2 years) clinical outcomes (MACE) 
of this complex subset of patients.
Results: A total of 1,274 pts were enrolled. Among them, 459 pts (36%) had ACS as the initial clinical presentation (13% of STEMI). Most pts were 
men (67%) with mean age of 63 years. DM was highly prevalent in this subset (37%).There was 6.5% of angiographic detected thrombus. Stent/
patient average was 1.2 and mean lesion length and RVD were 23.8mm and 2.9mm. The chart displays the survival-free of MACE curve up to 2 years 
of clinical FU. Definite/probable stent thrombosis rate was of 0.6%.
Conclusions: The use of Supralimus for the treatment of ACS patients demonstrated excellent performance and safety up to two years of FU, with 
very low rate of overall MACE and stent thrombosis. This novel technology may represent an alternative approach in the treatment of this complex 
subset of patients.
